Preventive Health
Advanced technology
[PDF]Cell Therapy Enhances Survival in Lung Cancer Treatment
In a 5-year study, CAPRI cell therapy combined with chemotherapy improved survival for NSCLC patients versus chemotherapy alone. CAPRI-treated patients showed higher immune markers and longer survival, with manageable side effects, highlighting CAPRI’s potential as an effective adjuvant immunotherapy.
[PDF]CAPRI: A Promising Adoptive Cell Therapy for Cancer
Adoptive cell therapy (ACT) with CAPRI shows promise in cancer treatment. Studies link CAPRI-stimulated immune cells to improved outcomes. Early case series suggest CAPRI may outperform traditional ACT methods, warranting further investigation.
[PDF]HLA-Haploidentical Donor Immune Cell Infusion Safe in Childhood Cancer
A study at Sun Yat-sen University Cancer Center found HLA-haploidentical donor immune cell infusion (HDICI) safe for treating childhood malignancies. Over a year, 12 children received 92 HDICIs without serious adverse effects. Most remained in remission, showing HDICI’s potential as a safe treatment option.
[PDF]Intrapleural mCIK Cell Therapy Eases Symptoms in CDC Metastasis Patient
A 33-year-old male with aggressive kidney cancer (CDC) experienced symptom relief and reduced pleural fluid after treatment with modified cytokine-induced killer cells, indicating a promising therapy for pleural metastasis.
[PDF]CAPRI Method: A Novel Cancer Immunotherapy
The CAPRI method activates T cells using patient-derived monocytes without needing tumor cells. It rapidly creates powerful immune cells, showing efficacy in mice and breast cancer patients, with improved 5-year survival rates. The process is safe, fast, and effective against various cancers.
[PDF]Role of CD4 T Cells in Enhancing CD8 T-Cell Function for Chronic Infections and Cancer
CD4 T cells regulate CD8 T-cell responses in chronic viral infections. Studies show that without CD4 help, CD8 T cells become dysfunctional. CD4 T-cell immunotherapy, alone or with inhibitory receptor blockade, may treat CD8 T-cell dysfunction in chronic infections and cancer.
[PDF]Enhancing Cancer Treatment with Targeted Immunotherapies
T-cell responses can target cancer cells, but inhibitory signals like PD-L1 hinder this. New immunotherapies target and overcome such inhibition. Combining therapies that address different steps of the Cancer-Immunity Cycle may enhance effectiveness. Immunotherapy is poised to become a crucial cancer treatment.
